Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and feasibility of electrical muscle stimulation in patients undergoing autologous and allogeneic stem cell transplantation or intensive chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2018

Same author

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.

British journal of haematology·2017

Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

[Treatment of diffuse large B-cell lymphoma].

B Gleissner¹, C Zwick, M Pfreundschuh

¹Klinik für Innere Medizin I, Universitätsklinikum Saarland, Homburg. beate.gleissner@uniklinikumk-saarland.de

Deutsche Medizinische Wochenschrift (1946)

|September 4, 2008

Summary

This summary is machine-generated.

Diffuse large B-cell lymphoma (DLBCL) is a common lymphoma. Clinical risk factors like age and stage help tailor treatments, improving patient outcomes with regimens such as R-CHOP.

Related Experiment Videos

Last Updated: Jul 2, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

Oncology
Hematology
Immunology

Background:

Diffuse large B-cell lymphoma (DLBCL) constitutes 40% of all lymphoma cases.
Treatment advances include dose-dense chemotherapy and rituximab (a CD20 monoclonal antibody).

Observation:

Clinical risk factors identified at diagnosis are crucial for risk stratification.
Key factors include age, stage, lactate dehydrogenase (LDH) levels, ECOG performance status, and extranodal involvement.

Findings:

Risk stratification enables personalized modifications of the standard R-CHOP regimen.
These adaptations aim to optimize treatment efficacy based on individual patient profiles.

Implications:

Personalized risk-adapted therapy can significantly improve DLBCL prognosis.
This approach highlights the importance of comprehensive clinical evaluation for lymphoma management.